ORIENT BIO マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Jae-Jin Chang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	0.8%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Would ORIENT BIO (KRX:002630) Be Better Off With Less Debt?

May 01

Is ORIENT BIO (KRX:002630) Weighed On By Its Debt Load?

Jan 16

CEO（最高経営責任者

Jae-Jin Chang (63 yo)

no data

在職期間

Mr. Jae-Jin Chang serves as the Chief Executive Officer of Bio Genomics, Inc. Mr. Chang serves as President, Chief Executive Officer and Chairperson of ORIENT BIO Inc. He completed graduate studies at Konk...

ORIENT BIO マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Inotiv, Inc. (NasdaqCM:NOTV) acquired Orient BioResource Center, Inc. from ORIENT BIO Inc. (KOSE:A002630) for $51.3 million.

Second quarter 2022 earnings released: ₩2.00 loss per share (vs ₩81.00 loss in 2Q 2021)

First quarter 2022 earnings released: EPS ₩23.00 (vs ₩4.00 loss in 1Q 2021)

Full year 2021 earnings released: ₩135 loss per share (vs ₩116 loss in FY 2020)

Would ORIENT BIO (KRX:002630) Be Better Off With Less Debt?

Third quarter 2021 earnings released: EPS ₩34.00 (vs ₩4.00 loss in 3Q 2020)

Is ORIENT BIO (KRX:002630) Weighed On By Its Debt Load?

New 90-day high: ₩1,950

New 90-day low: ₩1,230

New 90-day low: ₩1,405

Second quarter 2021 earnings released: ₩81.00 loss per share

ORIENT BIO Inc.(KOSE:A002630) dropped from S&P Global BMI Index

New 90-day high - ₩2,015

ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.

ORIENT BIO Inc. (KOSE:A002630) agreed to acquire an additional 29.74% stake in Orient Electronics Co.,Ltd. for KRW 6.7 billion.

New 90-day high - ₩785

CEO（最高経営責任者

在職期間

ORIENT BIO マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Inotiv, Inc. (NasdaqCM:NOTV) acquired Orient BioResource Center, Inc. from ORIENT BIO Inc. (KOSE:A002630) for $51.3 million.

Second quarter 2022 earnings released: ₩2.00 loss per share (vs ₩81.00 loss in 2Q 2021)

First quarter 2022 earnings released: EPS ₩23.00 (vs ₩4.00 loss in 1Q 2021)

Full year 2021 earnings released: ₩135 loss per share (vs ₩116 loss in FY 2020)

Would ORIENT BIO (KRX:002630) Be Better Off With Less Debt?

Third quarter 2021 earnings released: EPS ₩34.00 (vs ₩4.00 loss in 3Q 2020)

Is ORIENT BIO (KRX:002630) Weighed On By Its Debt Load?

New 90-day high: ₩1,950

New 90-day low: ₩1,230

New 90-day low: ₩1,405

Second quarter 2021 earnings released: ₩81.00 loss per share

ORIENT BIO Inc.(KOSE:A002630) dropped from S&P Global BMI Index

New 90-day high - ₩2,015

ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.

ORIENT BIO Inc. (KOSE:A002630) agreed to acquire an additional 29.74% stake in Orient Electronics Co.,Ltd. for KRW 6.7 billion.

New 90-day high - ₩785

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04